/ /

atopic dermatitis

February Clinical Considerations for NPs, PasIn our February Clinical Considerations, we take a look at treatment options for a few common skin disorders.
New hope for eczemaThe US Food and Drug Administration (FDA) has announced its approval of a new, corticoid-sparing ointment to treat mild to moderate atopic dermatitis in pediatric patients aged 2 years and older.
New guidelines for early peanut exposureNew recommendations for infant exposure to peanuts to prevent peanut allergy address something many pediatricians have long suspected: Early exposure to peanuts, even in infants that have eczema, could prevent development of peanut allergy.
Guidelines recommend early peanut introductionExperts weigh in on what to know about the new addendum to the peanut allergy prevention guidelines.
January Clinical Considerations for NPs, PAsThis month, we take a look at when to use biologics, advances in pediatric Atopic Dermatitis (AD), and how Trump’s presidency might impact dermatology.
Research suggests new approaches to treat AD
Research suggests new approaches to treat ADResearch aimed at understanding the host-microbial interface in atopic dermatitis is ongoing but already providing insights for novel therapeutic strategies.
Dermatology’s 2017 Game ChangersSeveral dermatologists go over what they're most excited about to see in 2017 in a number of different topics ranging from AD treatment to off-label technology use, to more male patients.
December Clinical Considerations for NPs, PAsIn this month's Clinical Considerations, we take a look at AD and bullying, whether or not derms are doing enough for psoriasis patients, and the potential of Epicutaneous immunotherapy.
Novel immunomodulators expected to usher in new therapeutic eraA number of systemic and topical treatments for atopic dermatitis are being developed that feature novel mechanisms of action targeting the inflammatory axes involved in the disease.
Study offers new insight into pediatric eczemaResearchers have identified the skin phenotype of pediatric atopic dermatitis (AD) — a finding that challenges the notion of filaggrin's central role in the disease.